Superworth

Insight Molecular Diagnostics EPS IMDX

Diluted earnings per share by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
−$1.49
Latest quarter, Q2 FY26
−$0.31
Fiscal year 2025
−$1.62

Insight Molecular Diagnostics' earnings per share was −$1.49 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.31.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.62n/a
FY2024−$4.40n/a
FY2023−$3.44n/a
FY2022−$12.92n/a
FY2021−$9.40n/a
FY2020−$3.60n/a
FY2019−$8.60n/a
FY2018−$8.40n/a
FY2017−$12.80n/a
FY2016−$8.60n/a
FY2015−$8.20n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.31n/a−$1.49
Q1 FY26−$0.12n/a−$1.48
Q4 FY25−$0.72n/a−$1.62
Q3 FY25−$0.34n/a−$2.83
Q2 FY25−$0.30n/a−$3.47
Q1 FY25−$0.26n/a−$3.53
Q4 FY24−$1.93n/a−$4.40
Q3 FY24−$0.98n/a−$4.43
Q2 FY24−$0.36n/a−$4.26
Q1 FY24−$1.13−383%−$4.97
Q4 FY23−$1.96n/a−$3.44
Q3 FY23−$0.81n/a−$9.10

Against its peers

Companies in Healthcare nearest Insight Molecular Diagnostics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
IMDXInsight Molecular Diagnostics−$1.49
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
APTAlpha Pro Tech$0.41+24% a year
ATNMActinium Pharmaceuticals$0.36
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
ELMDElectromed$1.31+56% a year
Peer median$0.41

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Insight Molecular Diagnostics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.